Novelix Pharmaceuticals Director Jivamohan Valluri Resigns, Warrant Conversion Complete

Novelix Pharmaceuticals Limited (formerly Trimurthi Limited) announced key corporate developments following its board meeting held on March 30, 2026, at the company's registered office in Hyderabad. The meeting, which commenced at 5:00 PM and concluded at 6:30 PM, addressed warrant conversion and a director resignation.

Warrant Conversion and Share Allotment

The board approved the allotment of 11,50,000 equity shares with a face value of Rs. 10.00 each at an issue price of Rs. 20.00 per share, including a premium of Rs. 10.00 per share. This allotment resulted from warrant holders exercising their conversion option, with warrant holders paying the remaining 75% of the issue price (Rs. 15.00 per warrant).

Parameter: Details Shares Allotted: 11,50,000 equity shares Issue Price: Rs. 20.00 per share Face Value: Rs. 10.00 per share Premium: Rs. 10.00 per share Amount Raised: Rs. 1,72,50,000

The warrant conversion was part of a larger preferential issue of 15,000,000 warrants originally allotted on January 10, 2025. The warrants were issued following a special resolution passed at an Extra-Ordinary General Meeting on November 18, 2024, with in-principle approval from BSE Limited received on December 31, 2024.

Allottee Details

The equity shares were allotted to two strategic investors from the promoter and promoter group category:

Allottee Name: Shares Allotted SRINIDHI FINE-CHEMICALS LLP: 11,00,000 NARAHARI BELIDE: 50,000

Impact on Share Capital

Following the allotment, the company's paid-up equity capital increased significantly:

Metric: Before Allotment After Allotment Paid-up Capital: Rs. 1,99,35,000 Rs. 2,10,85,000 Number of Shares: 1,99,35,000 2,10,85,000 Face Value per Share: Rs. 10.00 Rs. 10.00

Director Resignation Details

The board considered and approved the resignation of Mr. Jivamohan Divakar Valluri (DIN: 09218013), Non-Executive Director, effective from the closure of business hours on March 30, 2026. In his resignation letter, Valluri cited pre-occupation and other personal commitments as reasons for stepping down.

Resignation Details: Information Director Name: Jivamohan Divakar Valluri DIN: 09218013 Position: Non-Executive Non-Independent Director Effective Date: March 30, 2026 Reason: Pre-occupation and personal commitments Other Directorships: Nil

Consequent to his resignation, Valluri also stepped down from his positions as member of the Audit Committee, Nomination & Remuneration Committee, and as Chairperson of the Stakeholders' Relationship Committee. He confirmed that there were no material reasons for his resignation beyond those stated.

Regulatory Compliance

Both announcements were made in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The company has submitted the required details to BSE Limited for dissemination through their website. The resignation intimation was signed by Venkateshwarlu Pulluru, Whole-time Director (DIN: 02076871).

Novelix Pharmaceuticals Limited has successfully completed a preferential share allotment to investor Mallela Venkataramna Reddy, with formal regulatory disclosures submitted to BSE Limited on February 17, 2026. The transaction involved the allotment of 3,30,000 equity shares representing 1.66% of the company's share capital, completed on February 12, 2026.

Regulatory Compliance and Documentation

The company has submitted comprehensive disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The formal intimation was filed by Whole-time Director Venkateshwarlu Pulluru to BSE Limited, where Novelix Pharmaceuticals shares are listed under scrip code 536565.

Parameter Details Allottee Mallela Venkataramna Reddy Category Non-Promoter Shares Allotted 3,30,000 Percentage of Total Capital 1.66% Allotment Date February 12, 2026 Disclosure Date February 17, 2026

Shareholding Structure Changes

The preferential allotment has significantly altered the investor's stake in the company. The detailed shareholding pattern shows substantial increase in Reddy's ownership:

Holding Period Number of Shares Percentage of Share Capital Percentage of Diluted Capital Before Acquisition 15,00,000 8.52% 6.01% Shares Acquired 3,30,000 1.66% 1.21% After Acquisition 18,30,000 9.18% 6.71%

Company Capital Structure Enhancement

The preferential allotment has resulted in an expansion of Novelix Pharmaceuticals' equity share capital structure:

Capital Structure Amount Details Pre-allotment Capital ₹176,150,000 1,76,15,000 equity shares of ₹10 each Post-allotment Capital ₹199,350,000 19,935,000 equity shares of ₹10 each Total Diluted Capital ₹266,850,000 Including 73,35,000 outstanding convertible warrants

Corporate Governance and Transparency

The transaction demonstrates adherence to regulatory requirements with proper documentation submitted to both BSE Limited and the company's board of directors. Novelix Pharmaceuticals, formerly known as Trimurthi Limited, maintains its registered office in Hyderabad, Telangana, and operates under CIN L67120TG1994PLC018956.

This preferential allotment represents investor confidence in Novelix Pharmaceuticals' business prospects and provides the company with additional capital for operational and growth requirements while maintaining full regulatory compliance.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.